検索結果

Product Development Policy | Research & Development | SENJU Pharmaceutica

etina, cause bleeding and edema. In recent drug therapies, intravitreal injection of antibody drugs targeting the vascular endothelial growth factor (VEGF) protein, which increases angiogenesis and le...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

ctivitis, based on a compound licensed from Tanabe Pharma Corporation. Allergic conjunctivitis, the target indication of SJP-0049, is an inflammatory disease of the conjunctiva mainly mediated by Type...

announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...